Intellectual Property India Publishes Patent Application for 'Solid Dosage Forms Of A Plasma Kallikrein Inhibitor' Filed by Rezolute, Inc.

MUMBAI, India, Nov. 7 -- Intellectual Property India has published a patent application (202517056695 A) filed by Rezolute, Inc., Redwood City, U.S.A., on June 12, for 'solid dosage forms of a plasma kallikrein inhibitor.'

Inventor(s) include Burke, Michael; Breit, Jeffrey; Wald, Randy; and Steinhauff, William.

The application for the patent was published on Nov. 7, under issue no. 45/2025.

According to the abstract released by the Intellectual Property India: "Described herein are high loading, stable solid dosage forms of a plasma kallikrein inhibitor, 1-benzyl-1H-pyrazole-4-carboxylic acid 4-carbamimidoylbenzylamide (Compound 1) or a pharmaceutically acceptable salt thereof. Methods of treatment of patients that will benefit from the effects of a plasma kallikrein inhibitor are also disclosed."

The patent application was internationally filed on Nov. 21, 2023, under International application No.PCT/US2023/080635.

Disclaimer: Curated by HT Syndication.